An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Expanded Access
N/A
Bayer Study Director
Study Director
Bayer
Australia: Department of Health and Ageing Therapeutic Goods Administration
15967
NCT01538680
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
New Britain, Connecticut 06052 | |
Bettendorf, Iowa 52722 | |
Alexandria, Minnesota 56308 | |
Albany, Georgia 31701 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Columbia, Missouri 65203 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Flint, Michigan 48532 | |
Louisville, Kentucky 40207 | |
McLean, Virginia 22101 | |
Kansas City, Kansas 66160 | |
Scarborough, Maine 04074 | |
Omaha, Nebraska 68114 | |
Metairie, Louisiana 70006 | |
Denver, Colorado | |
Boston, Massachusetts | |
Charlotte, North Carolina | |
Eugene, Oregon | |
Charleston, South Carolina | |
Lebanon, New Hampshire | |
Providence, Rhode Island 02908 | |
Washington, District of Columbia | |
Las Vegas, Nevada 89109 | |
Bismarck, North Dakota 58501 |